Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12802009 | 0.84 | HTR2A (0.41) | HTR2AHTR2CHTR2BTUBB1LMNA | |
| SCHEMBL31719426 | 0.84 | HTR2A (0.41) | HTR2AHTR2CHTR2BTUBB1LMNA | |
| SCHEMBL30662729 | 0.82 | HTR2A (0.37) | HTR2AHTR2CHTR2BTUBB1LMNA | |
| SCHEMBL22331174 | 0.82 | HTR2A (0.37) | HTR2AHTR2CHTR2BTUBB1LMNA | |
| SCHEMBL28892490 | 0.82 | L3MBTL1 (0.41) | HTR2AHTR2CHTR2BTUBB1MAPK1 | |
| SCHEMBL12648419 | 0.82 | HTR2A (0.42) | HTR2AHTR2CHTR2BANO1TUBB1 | |
| SCHEMBL10300147 | 0.80 | HTR2C (0.38) | HTR2AHTR2CHTR2BHTTTDP1 | |
| SCHEMBL5142101 | 0.80 | CA2 (0.41) | MAPK1HTTRAB9A | |
| SCHEMBL3109509 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BANO1TUBB1 | |
| SCHEMBL3105557 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BANO1TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957232-B | Benzodihydro oxazine compound, preparation method thereof and anti-tuberculosis application | 四川大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-116178389-A | Preparation method of linagoli | 浙江科聚生物医药有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-114957232-A | Benzo-dihydro-oxazine compound, preparation method thereof and anti-tuberculosis application thereof | 四川大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-1939204-B3 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2022-08-24 | — | — | EP | disclosed |
| EP-3021947-B1 | AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2147922-B1 | FUSED HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-2731436-B1 | 2-(PYRROLO[2,3-B]PYRIDINE-5-YL)-2-(T-BUTOXY)-ACETIC ACID DERIVATIVES AS HIV REPLICATION INHIBITORS FOR THE TREATMENT OF AIDS | VIIV HEALTHCARE UK LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| EP-2733534-B1 | COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINED PATTERN USING SAME | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-3021947-A1 | AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME | Global Alliance For Tb Drug Development (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9298094-B2 | Composition for forming fine pattern and method for forming fined pattern using same | MERCK PATENT GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1939204-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1369490-B1 | Method of preparing a composition containing hygromycin A and epi-hygromycin | PFIZER PROD INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1369490-A1 | Method of preparing a composition containing hygromycin A and epi-hygromycin | Pfizer Products Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1075483-B1 | HYGROMYCIN A DERIVATIVES | PFIZER PROD INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1075483-A2 | HYGROMYCIN A DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325900-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | SHBG, CYP19A1, NR5A1 | HTR2A 1721/4885HTR2C 1435/4885HTR2B 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.